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D espite careful donor selection, cancer transmissionremains a rare but dramatic complication of renal
transplantation. In the light of a case report, we ﬁrst
review recent evidence regarding the risk of cancer
transmission in kidney recipients. Second, we discuss
the difﬁcult task of assessing the beneﬁt–risk balance
in the decision process of accepting organs from cancer
patients.
CASE PRESENTATION
A 53-year-old man started hemodialysis in our center
for an unspeciﬁed glomerulopathy. He had a history
of hepatitis B, arterial hypertension, subclinical hypo-
thyroidism, and hypercholesterolemia. He received a
kidney from an unrelated brain-dead donor. Initial
immunosuppression at the time of transplantation con-
sisted of anti-interleukin-2 receptor, mycophenolate
mofetil, tacrolimus, and corticoids. There was no
complication during the immediate postoperative
period. The patient was discharged on the eighth post-
operative day and plasma creatinine continued to
decrease progressively during the follow-up in our
outpatient clinic to 1.5 mg/dl. After 100 days, the patient
was admitted to the emergency department for rectal
bleeding and abdominal discomfort. Plasma creatinine
was slightly increased (2.2 mg/dl) as were lactate dehy-
drogenase levels (463 U/l, normal range <225). Chest
radiography revealed multiple opacities suggestive of
metastases. The patient was then subjected to an
extensive work-up that included colonoscopy, bron-
choscopy, full-body positron emission tomography
scan, cholangio-magnetic resonance imaging, computed
tomography of the abdomen and chest, gastroscopy, andInternational Reports (2016) -, -–-computed tomography of the brain. The colonoscopy
did not show any other pathologic lesion than hemor-
rhoids. CT revealed an inﬁltration of the renal graft, as
well as several lesions in both lungs and adenopathies in
multiple sites (mediastinum, retroperitoneum, and
femoral) compatible with metastases. Plasma levels of
cancer tumor markers were abnormal: carbohydrate
antigen 19.9 was elevated (240 N < 19 kU/l) and carci-
noembryonic antigen, carbohydrate antigen 125, and
beta-HCG (human chorionic gonadotropin) were slightly
elevated. Prostate-speciﬁc antigen and alpha-fetoprotein
were in the normal range. A biopsy of the renal graft was
performed 10 days after admission, leading to the his-
tologic diagnosis of a low differentiated adenocarcinoma
(Figure 1a). Immunohistologic characterization of the
tumor cells showed a positivity for anti-cytokeratin 7
(Figure 1b), whereas other markers were negative
(anti-cytokeratin 20, anti-p63, anti-cytokeratin 5.6, anti-
thyroid transcription factor 1, anti-ER [estrogen receptor],
PR [progesterone receptor], and gross cystic disease ﬂuid
protein 15), suggesting a primary tumor of upper gastric,
pulmonary, or gynecologic origin.
We were later informed that 2 additional recipients
from the same donor (kidney and liver) had also
developed cancer. The liver recipient underwent a
partial resection of the liver graft after conﬁrmation of
cancer lesion, and the second kidney recipient was
explanted but already had livermetastases at the time of
surgery. Finally, the donor origin of the tumor
was conﬁrmed by a caryotype and a polymerase
chain reaction ampliﬁcation of the microsatellite DNA
region on the tumoral part of the biopsy (caryotype
of the tumor was XX and the recipient was XY;
polymerase chain reaction ampliﬁcation: 79% of
cells of donor origin). The patient was explanted,1
Figure 1. Histologic analysis of the kidney graft. (a) Atrophic tubules (arrows) and tumoral cells (dash-dotted line) are seen at low magniﬁcation
(100) on hematoxylin and eosin (H&E) stained section. (b) On high magniﬁcation (400) and with periodic acid-Schiff coloration (PAS), mucine
vacuole secretions are obvious (arrow) with tumoral cells (dash-dotted line). (c) On immunohistochemistry, tumoral cells are positive for
carbohydrate antigen (CA) 19.9 staining.
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dialysis was resumed. Additional immunohistologic
tests were performed on the surgical piece (Table 1).
Chemotherapy consisting of cisplatin in association
with 5-ﬂuorouracil was started. After 5 cures of this
regimen, positron emission tomography scan and
computed tomography of the chest demonstrated a
dramatic improvement of the metastatic lesions.
Moreover, we observed the apparition of donor-speciﬁc
anti-human leukocyte antigen antibodies, which had
been impossible to detect before transplantation.Table 1. Immunohistologic characterization of the tumor cells.
Additional immunohistologic tests were performed on the graft
biopsy and graft explant
Markers Results
Antibody anti-CK7 þ
Antibody anti-CK20 –
Antibody anti-p63 –
Antibody anti-CK5.6 –
Antibody anti-TTF1 –
Antibody anti-ER, PR, GCDFP15 –
Antibody anti-34BE12 þ
Antibody anti-AE1-AE3 þ
Antibody anti-CA19.9 þ
Antibody anti-CA125 Locally þ
Antibody anti-calretinin –
Antibody anti-CEA þ
Antibody anti-cytokeratin 5.6. –
Antibody anti-cytokeratin 7 þ
Antibody anti-cytokeratin 20 –
Antibody anti-cytokeratin 14 Locally þ
Antibody anti-cytokeratin 19 þ
Antibody anti-EMA þ
Antibody anti-HMB45 –
Antibody anti-inhibin alpha þ
Antibody anti-p63 –
Antibody anti-S100 –
Antibody anti-TTF1 –
Antibody anti-vimentin –
CA, carbohydrate antigen; CEA, carcinoembryonic antigen; CK, cytokeratin; EMA,
epithelial membrane antigen; ER, estrogen receptor; GCDFP, gross cystic disease ﬂuid
protein; HMB45, human melanoma black 45; PR, progesterone receptor; TTF, thyroid
transcription factor.
2Also, the blood level of carbohydrate antigen 19.9
marker had drastically decreased to 55 kU/l. As the
evolution and/or patient’s reaction proved better than
expected, we suspected that the patient’s immune
system was able to control the disease. We therefore
decided to stop chemotherapy and to carefully follow
up any further development. Twenty months after
chemotherapy was stopped, carbohydrate antigen 19.9
tumor marker remained in the normal range and no sign
of cancer progression was found.
DISCUSSION
Inadvertent transmission of tumor remains a rare but
dramatic complication in organ transplantation. The
current recommendation for treatment of donor-
transmitted tumors in kidney transplantation is
cessation of immunosuppression, to allow rejection of
the allograft and transplanted cancer cells.1 After
rejection has been established, the donor organ is
removed. Chemotherapy and/or radiotherapy are
usually performed depending on tumor characteris-
tics. However, despite aggressive management prog-
nosis remains poor. The survival rate was recently
assessed.2 Prognosis depends on the extension of
cancer at diagnosis, tumor type (eg, 5-year survival
rate is less than 30% for a melanoma and more than
70% for a renal carcinoma, respectively) and cancer
differentiation. A series of strict donor selection
criteria have been ﬁxed to minimize the risk of cancer
transmission in this context, thus limiting the number
of organs available. However, patients remaining on
dialysis also exhibit a bad survival rate. Indeed, ac-
cording to the UK National Transplant List, up to 6%
of patients awaiting kidney transplants die or are
withdrawn before a graft becomes available.3 Fifteen
cases of donor-transmitted cancers were recorded in
the UK between 2001 and 2010, whereas more than
4000 patients died on the waiting list spanning the
same period.4 Using organs from selected donors withKidney International Reports (2016) -, -–-
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overall beneﬁt in patients’ survival. For nephrologists,
balancing the risks and beneﬁts in this context would
thus inevitably represent an additional challenge. We
discuss recently published data and try to highlight
the critical points.
According to the literature, approximately 7% of
deceased donors suffer from an unknown cancer at the
time of organ removal, 60% of which have no apparent
contraindication to organ donation.5 This staggering
number contrasts with the low frequency of tumor
transmission from donors with no known tumor, which
has been estimated at only 0.01% to 0.05% per trans-
planted organ.1,6 In addition, only a limited number of
cases have been described since the early years of renal
transplantation. A recent review that systematically
analyzed all case reports, case series, and registry
studies reports 104 donor-transmitted cancer cases in
which the outcomes of kidney transplant recipients
were described.2 The most common transmitted cancer
types were renal cancer (19%), followed by mela-
noma (17%), lymphoma (14%), and lung cancer
(9%).2 Regarding deceased donors, there is no way to
be absolutely sure that a speciﬁc donor has no hidden
malignancy. One should argue that systematic donor
autopsy could minimize risk of transmission. This
procedure results in a signiﬁcant human workload, is
expensive, and not always feasible on a systematic
basis. In addition, it may skip small malignant lesions.
Several risk factors for cancer transmission were
identiﬁed in donor patients with no known tumor.
These factors included donor age above 45 years, the
occurrence of nontraumatic cerebral hemorrhage that
could mask brain or metastatic tumors and mis-
diagnosed primary central nervous system (CNS) tu-
mors masking tumor metastases.6–8 In addition,
statistics showed that donors after circulatory death
more frequently displayed a history of cancer as
compared with donors after brain death (2.3% vs.
1.5%).9 Donors with a previous history of cancer could
represent an important source of organs considering
that the risk of cancer transmission may be lower than
previously estimated. Indeed, retrospective studies
suggest that 1% to 2% of deceased donors have a
previous history of cancer.10,11 An analysis of Organ
Procurement and Transplantation Network/United
Network for Organ Sharing data identiﬁed 1069 donors
with a previous cancer history, resulting in 2508
transplants (including 1236 kidneys).10 Among these
were 642 cases with CNS malignancies (including 175
with glioblastoma multiforme), 140 with melanoma,
10 with lung cancers, 51 with lymphoma or leukemia,
38 with colorectal cancers, and 75 with ovarian cancers.
Approximately 30% of these patients had a cancer-freeKidney International Reports (2016) -, -–-interval of less than 5 years. Only 1 donor with a
glioblastoma multiforme transmitted fatal tumors to 3
recipients and 1 other donor with a melanoma trans-
mitted his cancer to a single recipient. More recently, a
study conducted in the UK among 17,639 donors found
that 202 of them (1.1%) had a history of cancer
(excluding patients with previous nonmelanoma skin
cancer or those with extracranial cancers diagnosed on
the day of donation).9 Among these, 73.8% had a CNS
malignancy and 61 had a cancer with an unacceptable
or high risk of transmission according to the current
guidelines. No cancer transmission was noted in the
133 recipients of these 61 donors. The authors conclude
that an additional survival beneﬁt of 944 life-years was
gained by transplanting organs from these donors with
an unacceptable and/or high risk of cancer 10 years
after transplantation. In the same study, data from
potential donors between 2009 and 2012 were
analyzed, but only 6 of them presented a history of
cancer classiﬁed as unacceptable and/or high risk with
no other contraindication to donation. In another study
conducted in the UK between 2003 and 2014, 61 donors
with an active or previous history of cancer were
identiﬁed among a total of 2546 kidney and liver
transplantations resulting in 71 transplanted organs for
71 recipients.12 Among these were 43 donors with CNS
malignancy (including 9 with glioblastoma grade IV
and 1 with glioblastoma grade III) and 18 with non-
CNS malignancies (including 4 recipients transplanted
from a donor with a previous history of lymphoma and
3 with a previous history of lung or breast cancer). One
kidney recipient developed donor-transmitted lung
cancer and one liver transplant recipient developed
donor-transmitted lymphoma. In cases where the donor
had a history of CNS cancer, contralateral renal cell
carcinoma, or ipsilateral resected renal cell carcinoma
however, none of the recipients developed cancer.
Similar results were found in another study evaluating
the risk-beneﬁt ratio in kidney transplantation from a
donor with a primary CNS cancer.13 In this study, 179
donors were identiﬁed with a primary intracranial
cancer, including 33 with high-grade malignancy (24
with grade IV gliomas and 9 with medulloblastomas).
No transmission of malignancy occurred among the 448
recipients of 495 organs transplanted from these do-
nors. Using these data, it was estimated that the use of
kidneys from a donor with a primary CNS tumor pro-
vides a further 8 years of life compared with a recipient
waiting for a donor with no primary CNS tumor.14
Therefore, the previous assessment of donors with
cancer as presenting an unacceptable and/or high risk
has been re-evaluated by several authors. Notably,
they suggest that selected donors with a previous
history of melanoma, breast, ovarian, or colonic3
NEPHROLOGY ROUNDS TER Baudoux et al.: Donor-transmitted cancer in kidney recipientscancer should be considered as donors at acceptable
risk.9 Others suggest that organs from donors with a
history of intracranial malignancy, including those
with high-grade tumors, should be considered and the
balance of risks and beneﬁts should be discussed with
the patient accordingly.13,15
CONCLUSION
To conclude, it remains obvious that clinicians diag-
nosing a malignancy after solid organ transplantation
that might be donor transmitted need to alert the orga-
nization in charge to take appropriate care of other
potentially affected recipients.16 Moreover, conﬁrma-
tion of the same type of cancer in other recipients from
the same donor is another clue for donor cancer trans-
mission diagnosis. Besides the mandatory reporting,
investigations in related cases could conﬁrm cancer
transmission. If this is not the case, a careful surveillance
could be considered as an alternative to organ removal.
As most cases of transmitted cancer developed during
14 months after transplantation,16 such screening and
follow-up protocols should be designed at least for this
critical period on an individual basis and after discussion
within a multidisciplinary team. In this perspective,
whole-body positron emission tomography scan has
been recently reported to successfully detect transmitted
lung cancer in an asymptomatic kidney recipient
7 months after donation.17
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